Breaking News

Moderna Expands mRNA Pipeline with Three New Programs

Programs are mRNA vaccine candidates against herpes simplex virus, varicella-zoster virus to reduce the rate of shingles and new checkpoint cancer vaccine.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna, Inc. is expanding its mRNA pipeline with three new development programs. The programs are mRNA vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) to reduce the rate of shingles and a new checkpoint cancer vaccine. HSV and VZV are latent viruses that remain in the body for after infection and can lead to medical conditions. Moderna now has five vaccine candidates against latent viruses in development, including against cytomegalovirus (CMV), Epstein-Barr ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters